Maxalt Related Published Studies
Well-designed clinical trials related to Maxalt (Rizatriptan)
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, cross-over, multicenter, Italian,
comparative study versus rizatriptan. [2011]
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. [2009.05]
Migraine treatment with rizatriptan and almotriptan: a crossover study. [2009.05]
Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. [2009.03]
Memantine in the preventive treatment of refractory migraine. [2008.10]
Effects of rizatriptan on the contingent negative variation in healthy women. [2008.09]
Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. [2008.06]
Effects of rizatriptan on the contingent negative variation in healthy women. [2008.05.28]
Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. [2008.03]
Elimination of Migraine-Associated Nausea in Patients Treated with Rizatriptan Orally Disintegrating Tablet (ODT): A Randomized, Double-Blind, Placebo-Controlled Study. [2007.11.28]
A randomized trial of rizatriptan in migraine attacks in children. [2006.10.10]
Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. [2006.07]
Efficacy of Rizatriptan 10 mg administered early in a migraine attack. [2006.06]
Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. [2006.03]
Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. [2006.01]
Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans. [2005.01]
Evaluation of the bioequivalence and pharmacokinetics of two formulations of rizatriptan after single oral administration in healthy volunteers. [2005]
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. [2004.10]
Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. [2004.07]
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. [2004.06.28]
Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. [2003]
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects. [2002.07]
Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. [2002.05]
CNS effects of sumatriptan and rizatriptan in healthy female volunteers. [2002.05]
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. [2002.01]
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. [2002]
Pharmacokinetics of rizatriptan in healthy elderly subjects. [2001.10]
Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. [2001.09]
Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. [2001.07]
Long-term efficacy and tolerability of rizatriptan wafers in migraine. [2001.06.01]
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. [2001]
Within-patient consistency of response of rizatriptan for treating migraine. [2000.11.28]
Work and productivity loss in the rizatriptan multiple attack study. [2000.11]
Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. [2000.07]
Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. [2000.06]
A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. [2000.03]
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. [1999.08]
Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. [1999.06]
Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. [1999.04]
Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. [1999.02]
Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. [1999]
Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. [1998.12]
Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. [1998.11]
Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. [1998.11]
Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. [1998.11]
A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. [1998.09]
Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. [1998.04]
Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. [1997.12]
Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. [1997.10]
Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. [1997.01]
Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. [1996.11]
Well-designed clinical trials possibly related to Maxalt (Rizatriptan)
Gender and triptan efficacy: a pooled analysis of three double-blind, randomized,
crossover, multicenter, Italian studies comparing frovatriptan vs. other
triptans. [2014]
Efficacy of frovatriptan and other triptans in the treatment of acute migraine of
hypertensive and normotensive subjects: a review of randomized studies. [2013]
Frovatriptan vs. other triptans for the acute treatment of oral
contraceptive-induced menstrual migraine: pooled analysis of three double-blind,
randomized, crossover, multicenter studies. [2013]
Sumatriptan (subcutaneous route of administration) for acute migraine attacks in
adults. [2012]
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. [2011.01]
Published and not fully published double-blind, randomised, controlled trials
with oral naratriptan in the treatment of migraine: a review based on the GSK
Trial Register. [2011]
A comparison of migraine patients with and without allodynic symptoms. [2009.10]
Acute treatment and prevention of menstrually related migraine headache: evidence-based review. [2008.04.22]
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. [2008.04.15]
Influence of an e-mail with a drug information attachment on sales of prescribed drugs: a randomized controlled study. [2007.10.18]
Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. [2007.10.03]
A review of recent clinical experience with almotriptan. [2006]
Symptomatic treatment of migraine in children: a systematic review of medication trials. [2005.08]
Multiple attack study on the available triptans in Italy versus placebo. [2005.07]
Current perspectives on effective migraine treatments: are small clinical differences important for patients? [2003]
Determinants of migraine-specific quality of life. [2002.10]
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. [2001.08]
Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. [2000.10]
The scientific basis of medication choice in symptomatic migraine treatment. [1999.11]
Validation of a migraine work and productivity loss questionnaire for use in migraine studies. [1999.06]
Pilot study of MK-462 in migraine. [1996.04]
Pharmacokinetics and food interaction of MK-462 in healthy males. [1996.01]
Other research related to Maxalt (Rizatriptan)
Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in
patients with moderate-to-severe migraine. [2014]
Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a
double-blind trial. [2012]
Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. [2011.12]
Rizatriptan for Treatment of Acute Migraine in Patients Taking Topiramate for Migraine Prophylaxis. [2011.11.11]
Efficacy of parecoxib, sumatriptan, and rizatriptan in the treatment of acute migraine attacks. [2011.11]
Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database. [2011.03]
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011]
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2010.09.23]
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2010.08.05]
Arterial spin-labeled MRI study of migraine attacks treated with rizatriptan. [2010.06]
Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis. [2010.04]
Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. [2009.10]
Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. [2009.07]
Acute migraine treatment with rizatriptan in real world settings - focusing on treatment strategy, effectiveness, and behavior. [2009.02]
Ten years of rizatriptan: from development to clinical science and future directions. [2009.02]
Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. [2008.09]
Rizatriptan Efficacy in ICHD-II Pure Menstrual Migraine and Menstrually Related Migraine. [2008.04.14]
A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future. [2008.04]
Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. [2008.02]
Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model: A Prospective Subgroup Analysis of the Rizatriptan TAME (Treat A Migraine Early) Studies. [2007.11.13]
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. [2007.09]
WITHDRAWN: Rizatriptan for acute migraine. [2007.07.18]
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. [2007.07]
Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. [2007.06.07]
|